Cingulate Inc. (CING) stock
Close on Nov 11, 2026Market cap $67.47MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $67.47M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.88
- Dividend yield
- –
- Free cash flow yield
- -31.03%
Fundamentals
- Net income
- -$28.80M
- EPS, diluted
- -$3.68
- Free cash flow
- -$20.94M
- Book value per share
- $1.78
- Diluted shares
- 13M
Trading
- Next earnings
- Nov 12, 2026 (estimated, before the open)
- Previous close
- $4.56
- Open
- $4.50
- Day's range
- $4.33 – $4.75
- Volume
- 139,145
- Average volume (20 days)
- 137,333
- Beta (5 years)
- 2.08
- 52-week range
- $3.16 – $11.89
- RSI (14 days)
- 47.0
- Volatility (1 year)
- 87.6%
- Relative volume
- 0.95×
- WACC
- 15.3%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CING | S&P 500 | Difference | CING per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -5.1% | -2.4% | −2.7 pts | ||
| 3 months | -10.8% | -1.2% | −9.6 pts | ||
| Year to date | +6.9% | +12.3% | −5.4 pts | ||
| 1 year | +26.4% | +12.4% | +14.0 pts | ||
| 3 years | -93.9% | +78.8% | −172.7 pts | -60.6% | +21.4% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cingulate filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Update
- Update
- Results
About Cingulate
Pharmaceutical Preparations
Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing and advancing next-generation pharmaceutical products. The company utilizes its proprietary Precision Timed Release drug delivery platform technology, which incorporates an Erosion Barrier Layer designed to release drug substances at specific, pre-defined intervals in once-daily, multi-dose tablets. Its pipeline centers primarily on the treatment of Attention Deficit/Hyperactivity Disorder and anxiety. Candidate medications include CTx-1301 and CTx-1302 for pediatric, adolescent, and adult patients diagnosed with Attention Deficit/Hyperactivity Disorder, alongside CTx-2103 for the treatment of generalized anxiety disorder.
Company profile, executives and historyCingulate stock: common questions
What is Cingulate's stock price?
CING closed at $4.64 on Nov 11, 2026, up 1.75% on the day. Over the past 52 weeks it traded between $3.16 and $11.89.
What is Cingulate's market cap?
Cingulate was worth $67.47M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CING's P/E ratio?
Cingulate lost money over the twelve months to Jun 30, 2026 (diluted EPS -$3.68), so it has no meaningful P/E ratio.
Does Cingulate pay a dividend?
No. Cingulate has not paid a cash dividend over the last twelve months.
When does Cingulate report earnings next?
Cingulate is expected to report Q3 FY2026 results on Nov 12, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CING stock performed over the past year?
Including dividends, CING returned +26.4% over the past year, against +12.4% for the S&P 500.
Who are Cingulate's competitors?
Companies most similar to Cingulate by business, industry and size include IXHL, AYTU, CMPS, PBM, NERV.
See a number that looks wrong?